Iqvia Holdings Inc (NYSE:IQV) insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total value of $999,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Iqvia Holdings Inc (NYSE IQV) opened at $103.00 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.22 and a current ratio of 1.22. Iqvia Holdings Inc has a 12 month low of $74.80 and a 12 month high of $110.67. The stock has a market capitalization of $21,420.00, a price-to-earnings ratio of 355.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.61.
Iqvia (NYSE:IQV) last released its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the prior year, the company posted $1.00 earnings per share. The business’s revenue for the quarter was up 77.6% compared to the same quarter last year. equities analysts anticipate that Iqvia Holdings Inc will post 4.62 EPS for the current fiscal year.
IQV has been the subject of a number of recent research reports. KeyCorp restated a “buy” rating and issued a $100.00 target price on shares of Iqvia in a research note on Sunday, September 24th. Robert W. Baird restated a “hold” rating and issued a $98.00 target price on shares of Iqvia in a research note on Monday, October 9th. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $107.00 target price for the company in a research note on Wednesday, October 11th. Credit Suisse Group restated an “outperform” rating and issued a $110.00 target price (up from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Finally, Stifel Nicolaus upgraded Iqvia from a “hold” rating to a “buy” rating and increased their price objective for the stock from $92.00 to $128.00 in a research note on Friday, October 27th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $107.79.
ILLEGAL ACTIVITY NOTICE: “Iqvia Holdings Inc (IQV) Insider Sells $999,700.00 in Stock” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2018/01/22/iqvia-holdings-inc-iqv-insider-sells-999700-00-in-stock.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.